Phase 1/2 clinical trial to evaluate the safety and efficacy of daily intravitreal injections of KUS121 for three days in patients with non-arteritic central retinal artery occlusion

Trial Profile

Phase 1/2 clinical trial to evaluate the safety and efficacy of daily intravitreal injections of KUS121 for three days in patients with non-arteritic central retinal artery occlusion

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs KUS 121 (Primary)
  • Indications Retinal vascular occlusion
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top